Galectin Therapeutics (Nasdaq: GALT) announced that a preclinical study in a ... were treated after the development of disease with either a vehicle control (n=8) or GR-MD-02 (n=9) administered orally five days out of seven for a total of four weeks. ...

21 people liked this